Recent advances in the evidence-based management of non-small cell lung cancer: Current diagnostic approaches, molecular profiling, precision oncology, systemic therapies, surgical management, radiotherapy, and future therapeutic directions

https://doi.org/10.53730/ijhs.v7nS1.15992

Authors

  • Nader Saad Awad Al-Mutairi National Guard Health Affairs
  • Mashan Mashal Hubaylis Alharthi National Guard Health Affairs
  • Shaie Saleh National Guard Health Affairs
  • Hzam Alkorbi Zid Aldossri National Guard Health Affairs
  • Mohammad Naseer Ali Alqahtani National Guard Health Affairs
  • Faisal Zabin Hashar Alotaibi National Guard Health Affairs
  • Muteb Abdullah Almutairi National Guard Health Affairs
  • Abdullah Saleh Mohammed Alotaibi National Guard Health Affairs
  • Mohammed Khalaf Alruqi National Guard Health Affairs
  • Abdullah Abdalalhelal National Guard Health Affairs

Keywords:

Non-small cell lung cancer, NSCLC, molecular biomarkers, precision medicine, EGFR, ALK, KRAS, BRAF, chemotherapy, radiotherapy, surgery, targeted therapy

Abstract

Background: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and remains one of the leading causes of cancer-related mortality worldwide. Despite improvements in early detection and multidisciplinary care, many patients are diagnosed with advanced disease, resulting in poor long-term survival. Recent advances in molecular diagnostics, targeted therapies, immunotherapy, minimally invasive surgery, and precision medicine have substantially transformed the management of NSCLC and improved clinical outcomes for selected patient populations. Aim: This review aimed to summarize current evidence regarding the diagnosis and evidence-based management of NSCLC, with emphasis on risk factors, conventional treatment modalities, biomarker testing, and recent therapeutic advances that support personalized patient care. Methods: A comprehensive narrative review was conducted using published clinical guidelines, randomized controlled trials, systematic reviews, meta-analyses, and landmark studies addressing surgical treatment, chemotherapy, radiotherapy, molecular profiling, targeted therapy, and biomarker-directed management of NSCLC. Results: Surgical resection remains the preferred treatment for resectable early-stage disease, while platinum-based chemotherapy and radiotherapy continue to play central roles in locally advanced and metastatic NSCLC. Minimally invasive surgical approaches and stereotactic body radiation therapy have improved local disease control with lower treatment-related morbidity. 

Downloads

Download data is not yet available.

References

Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. 10.3322/caac.21208 DOI: https://doi.org/10.3322/caac.21208

American Cancer Society. Cancer Facts and Figures 2015. Available online: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf

National Cancer Institute. SEER Cancer Statistics Review, 1975-2011. Available online: http://seer.cancer.gov/csr/1975_2011/

Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83:355-67. 10.4065/83.3.355 DOI: https://doi.org/10.4065/83.3.355

Kenfield SA, Wei EK, Stampfer MJ, et al. Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 2008;17:198-204. 10.1136/tc.2007.022582 DOI: https://doi.org/10.1136/tc.2007.022582

Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-52. 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-# DOI: https://doi.org/10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#

Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokers--a review. Eur J Cancer 2012;48:1299-311. 10.1016/j.ejca.2012.03.007 DOI: https://doi.org/10.1016/j.ejca.2012.03.007

Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202. 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y DOI: https://doi.org/10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y

Stellman SD, Muscat JE, Hoffmann D, et al. Impact of filter cigarette smoking on lung cancer histology. Prev Med 1997;26:451-6. 10.1006/pmed.1997.0212 DOI: https://doi.org/10.1006/pmed.1997.0212

Brambilla E, Pugatch B, Geisinger K, et al. Large cell carcinoma. In: Travis W, Brambilla E, Müller-Hermelink H, et al. editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. WHO Press, Geneva, 2004:45-50.

Muscat JE, Stellman SD, Zhang ZF, et al. Cigarette smoking and large cell carcinoma of the lung. Cancer Epidemiol Biomarkers Prev 1997;6:477-80.

Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210. 10.1093/jnci/91.14.1194 DOI: https://doi.org/10.1093/jnci/91.14.1194

Whitrow MJ, Smith BJ, Pilotto LS, et al. Environmental exposure to carcinogens causing lung cancer: epidemiological evidence from the medical literature. Respirology 2003;8:513-21. 10.1046/j.1440-1843.2003.00497.x DOI: https://doi.org/10.1046/j.1440-1843.2003.00497.x

U.S. Dept. of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General, 2014. Available online: http://www.surgeongeneral.gov/library/reports/50-years-of-progress/

United States Environmental Protection Agency. Health Risk of Radon. Available online: https://www.epa.gov/radon/health-risk-radon

Krewski D, Lubin JH, Zielinski JM, et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 2005;16:137-45. 10.1097/01.ede.0000152522.80261.e3 DOI: https://doi.org/10.1097/01.ede.0000152522.80261.e3

Krewski D, Lubin JH, Zielinski JM, et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A 2006;69:533-97. 10.1080/15287390500260945 DOI: https://doi.org/10.1080/15287390500260945

Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 2005;330:223. 10.1136/bmj.38308.477650.63 DOI: https://doi.org/10.1136/bmj.38308.477650.63

Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000;44:565-601. 10.1093/annhyg/44.8.565 DOI: https://doi.org/10.1016/S0003-4878(00)00045-4

Berman DW, Crump KS. A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol 2008;38 Suppl 1:49-73. 10.1080/10408440802273156 DOI: https://doi.org/10.1080/10408440802273156

Stayner L, Kuempel E, Gilbert S, et al. An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers. Occup Environ Med 2008;65:613-9. 10.1136/oem.2007.035584 DOI: https://doi.org/10.1136/oem.2007.035584

van Loon AJ, Kant IJ, Swaen GM, et al. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med 1997;54:817-24. 10.1136/oem.54.11.817 DOI: https://doi.org/10.1136/oem.54.11.817

Spyratos D, Zarogoulidis P, Porpodis K, et al. Occupational exposure and lung cancer. J Thorac Dis 2013;5 Suppl 4:S440-5.

Vineis P, Husgafvel-Pursiainen K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 2005;26:1846-55. 10.1093/carcin/bgi216 DOI: https://doi.org/10.1093/carcin/bgi216

Pope CA, 3rd, Burnett RT, Thun MJ, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 2002;287:1132-41. 10.1001/jama.287.9.1132 DOI: https://doi.org/10.1001/jama.287.9.1132

Sellers T, Yang P. Familial and genetic influences on risk of lung cancer. In: King R, Rotter J, Motulsky A. editors. The Genetic Basis of Common Diseases. New York: NY, Oxford University, 2002:700-12.

Hwang SJ, Cheng LS, Lozano G, et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003;113:238-43. 10.1007/s00439-003-0968-7 DOI: https://doi.org/10.1007/s00439-003-0968-7

Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-42. 10.1038/nature06846 DOI: https://doi.org/10.1038/nature06846

Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7. 10.1038/nature06885

Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-22. 10.1038/ng.109 DOI: https://doi.org/10.1038/ng.109

Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e278S-313S. DOI: https://doi.org/10.1378/chest.12-2359

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909. 10.1136/bmj.311.7010.899 DOI: https://doi.org/10.1136/bmj.311.7010.899

Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13 Suppl 1:5-13. 10.1634/theoncologist.13-S1-5 DOI: https://doi.org/10.1634/theoncologist.13-S1-5

Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3488-515. 10.1200/JCO.2015.62.1342 DOI: https://doi.org/10.1200/JCO.2015.62.1342

Kelly K, Crowley J, Bunn PA, Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8. DOI: https://doi.org/10.1200/JCO.2001.19.13.3210

Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91. 10.1200/JCO.2002.02.068 DOI: https://doi.org/10.1200/JCO.2002.02.068

Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. 10.1056/NEJMoa011954 DOI: https://doi.org/10.1056/NEJMoa011954

Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24. 10.1200/JCO.2003.12.046 DOI: https://doi.org/10.1200/JCO.2003.12.046

Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004;15:419-26. 10.1093/annonc/mdh087 DOI: https://doi.org/10.1093/annonc/mdh087

Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-18. 10.1200/JCO.2007.14.1226 DOI: https://doi.org/10.1200/JCO.2007.14.1226

Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:234S-242S. DOI: https://doi.org/10.1378/chest.07-1378

Amini A, Yeh N, Gaspar LE, et al. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol 2014;9:210. 10.1186/1748-717X-9-210 DOI: https://doi.org/10.1186/1748-717X-9-210

Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010;95:32-40. 10.1016/j.radonc.2009.08.003 DOI: https://doi.org/10.1016/j.radonc.2009.08.003

Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-82. 10.1016/j.ijrobp.2008.11.042 DOI: https://doi.org/10.1016/j.ijrobp.2008.11.042

Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6. 10.1001/jama.2010.261 DOI: https://doi.org/10.1001/jama.2010.261

Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83:348-53. 10.1016/j.ijrobp.2011.06.2003 DOI: https://doi.org/10.1016/j.ijrobp.2011.06.2003

Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011;81:1352-8. 10.1016/j.ijrobp.2009.07.1751 DOI: https://doi.org/10.1016/j.ijrobp.2009.07.1751

Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5. 10.1513/pats.200809-107LC DOI: https://doi.org/10.1513/pats.200809-107LC

Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. 10.1056/NEJMoa040938 DOI: https://doi.org/10.1056/NEJMoa040938

Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. 10.1126/science.1099314 DOI: https://doi.org/10.1126/science.1099314

Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. 10.1073/pnas.0405220101 DOI: https://doi.org/10.1073/pnas.0405220101

Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 2008;10:493-5. 10.2353/jmoldx.2008.080105 DOI: https://doi.org/10.2353/jmoldx.2008.080105

Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-4. 10.1158/1078-0432.CCR-08-0646 DOI: https://doi.org/10.1158/1078-0432.CCR-08-0646

Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.

Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-51. 10.1038/nature12796 DOI: https://doi.org/10.1038/nature12796

Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 DOI: https://doi.org/10.1038/nature05945

Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24. 10.1158/1078-0432.CCR-08-1018 DOI: https://doi.org/10.1158/1078-0432.CCR-08-1018

Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83. 10.1158/1078-0432.CCR-08-0168 DOI: https://doi.org/10.1158/1078-0432.CCR-08-0168

Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 2011;6:905-12. 10.1097/JTO.0b013e3182111461 DOI: https://doi.org/10.1097/JTO.0b013e3182111461

Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-7. 10.1097/JTO.0b013e31815e8b60 DOI: https://doi.org/10.1097/JTO.0b013e31815e8b60

Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-15. 10.1038/modpathol.2009.2 DOI: https://doi.org/10.1038/modpathol.2009.2

Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. 10.1056/NEJMoa1006448

Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7:e31323. 10.1371/journal.pone.0031323 DOI: https://doi.org/10.1371/journal.pone.0031323

Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77. 10.1056/NEJMoa1408440 DOI: https://doi.org/10.1056/NEJMoa1408440

Daum G, Eisenmann-Tappe I, Fries HW, et al. The ins and outs of Raf kinases. Trends Biochem Sci 1994;19:474-80. 10.1016/0968-0004(94)90133-3 DOI: https://doi.org/10.1016/0968-0004(94)90133-3

Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19:4532-40. 10.1158/1078-0432.CCR-13-0657 DOI: https://doi.org/10.1158/1078-0432.CCR-13-0657

Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. 10.1038/nature00766

Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-3.

Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-51. 10.1200/JCO.2010.33.1280 DOI: https://doi.org/10.1200/JCO.2010.33.1280

Published

15-01-2023

How to Cite

Al-Mutairi, N. S. A., Alharthi, M. M. H., Saleh, S., Aldossri, H. A. Z., Alqahtani, M. N. A., Alotaibi, F. Z. H., Almutairi, M. A., Alotaibi, A. S. M., Alruqi, M. K., & Abdalalhelal, A. (2023). Recent advances in the evidence-based management of non-small cell lung cancer: Current diagnostic approaches, molecular profiling, precision oncology, systemic therapies, surgical management, radiotherapy, and future therapeutic directions. International Journal of Health Sciences, 7(S1), 3921–3936. https://doi.org/10.53730/ijhs.v7nS1.15992

Issue

Vol. 7 No. S1 (2023)

Section

Peer Review Articles
Copyright & Licensing

Copyright (c) 2023 International journal of health sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.

Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)